William Agbozo | Biochemistry, Genetics and Molecular Biology | Best Research Article Award

William Agbozo | Biochemistry, Genetics and Molecular Biology | Best Research Article Award

William Agbozo, Morehouse School of Medicine, Atlanta, GA 30310, USA. United States

William Kwaku Agbozo is a passionate Ghanaian biomedical researcher specializing in molecular and cell biology, particularly in the context of hemolysis-related complications in sickle cell disease and cerebral malaria. With a strong academic foundation from the University of Ghana, he has cultivated expertise through interdisciplinary training in physiology, biochemistry, and molecular sciences. Currently serving as a Research Scholar at Morehouse School of Medicine, Atlanta, he brings his research to life by utilizing advanced genomics and proteomics tools in both animal and human studies. His work has yielded peer-reviewed publications and international presentations, reflecting a commitment to translational science aimed at uncovering therapeutic targets. William has also made significant contributions as a lecturer at Central University, Ghana, mentoring students and guiding research projects. His career is driven by a desire to bridge clinical gaps in infectious and genetic diseases, focusing on real-world biomedical challenges in Africa and beyond.

Publication Profile

orcid

Education

William Agbozo’s academic journey began at the University of Ghana, where he earned his Bachelor of Science in Biochemistry (2008–2012). He continued at the same institution to pursue a Master of Philosophy in Physiology (2013–2015), equipping him with in-depth knowledge of human physiological mechanisms. Motivated by a growing interest in translational biomedical research, he embarked on a PhD in Molecular and Cell Biology (2018–2024, Viva pending), also at the University of Ghana. Throughout his academic path, William has maintained a strong interdisciplinary focus—integrating molecular biology, physiology, and cell biology with practical research on diseases like sickle cell and malaria. His PhD was conducted under the prestigious West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), supported by multiple international grants, where he gained valuable skills in omics technologies and disease modeling. His academic training reflects both scientific rigor and a deep-rooted commitment to addressing health burdens in Africa.

Experience

William Agbozo has over six years of academic and research experience. From 2017 to 2023, he worked as a Lecturer at the School of Medicine and Health Sciences, Central University, Accra, where he taught undergraduate physiology and supervised research and academic writing. In 2023, he transitioned to the Morehouse School of Medicine in Atlanta, USA, as a Research Scholar in the Department of Microbiology, Biochemistry & Immunology. At Morehouse, he is engaged in conceptualizing research ideas, contributing to grant proposals, and conducting laboratory experiments in molecular and translational research. He also leads data analysis and presents at major scientific meetings. His work spans across both African and U.S.-based biomedical institutions, reinforcing a global collaborative perspective. His experience reflects a balance of education, research, mentorship, and scientific communication, aimed at producing actionable insights for health systems managing genetic and infectious diseases.

Awards and Honors

William Agbozo has received several prestigious awards in recognition of his academic excellence and impactful research. He was awarded a PhD Fellowship (2018–2024) from the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP) under the World Bank African Centres of Excellence (ACE) initiative. Between 2019 and 2023, he secured research funding support from the Sickle Cell Disease Genomics Network of Africa (SickleGenAfrica), funded by the National Heart, Lung, & Blood Institute (U54HL141011). His scientific aptitude also earned him a place in the US Exchange Visitor Program as a research scholar at Morehouse School of Medicine (2023–2025), under the National Institute of Neurological Disorders and Stroke (R01NS125775). These honors reflect both his research potential and his growing international reputation in the fields of sickle cell disease and molecular medicine. They have empowered him to explore groundbreaking discoveries using both human samples and experimental models.

Research Focus

William Agbozo’s research centers on the molecular mechanisms of hemolysis-mediated injury in diseases such as sickle cell disease (SCD) and human cerebral malaria (HCM). His work investigates how excess free heme contributes to acute kidney injury (AKI) and brain damage, using humanized sickle cell mouse models and post-mortem human samples. He applies cutting-edge genomics and proteomics to map signaling pathways and identify biomarkers that may serve as protective or therapeutic targets. Through his research, William aims to bridge molecular biology with translational applications, developing insights that could lead to novel treatments or interventions. His work is especially impactful in regions heavily burdened by malaria and genetic blood disorders. By collaborating across institutions in Ghana and the United States, he brings an interdisciplinary and international lens to pressing biomedical problems affecting both African and global populations.

Publication Top Notes

📄 Hydroxyurea Mitigates Heme-Induced Inflammation and Kidney Injury in Humanized Sickle Cell Mice. (2025)
📄 Circulating biomarkers associated with pediatric sickle cell disease. (2024)
📄 Assessing knowledge of sickle cell disease and health beliefs on premarital genetic screening among healthcare trainees at a tertiary institution: A cross‐sectional study. (2023)
📄 Sociodemographic and medical characteristics of liver cirrhosis deaths in a Ghanaian tertiary hospital. (2022)
📄 Phosphomolybdenum Blue Detection – A Review of Characteristics, Achievements, Challenges and Future Prospects. (2020)
📄 Frequencies and ethnic distribution of ABO and RhD blood groups in the Volta region of Ghana, towards effective blood bank services. (2022)
📄 Frequency of ABO/Rhesus (D) blood groupings and ethnic distribution in the Greater‐Accra region of Ghana, towards effective blood bank inventory. (2019)
📄 Neuregulin-1 attenuates hemolysis-mediated kidney injury in humanized sickle cell mice. (Submitted)

Anna Lankoff | Genetics and Molecular Biology | Best Researcher Award

Anna Lankoff | Genetics and Molecular Biology | Best Researcher Award

Prof Anna Lankoff, Institute of Nuclear Chemistry and Technology, Centre for Radiobiology and Biological Dosimetry, Poland

Prof. Anna Lankoff is a distinguished scientist and educator renowned for her contributions to genotoxicology, nanotoxicology, and radiobiology. 👩‍🔬🧪 With over three decades of experience, she has made groundbreaking advancements in the study of ionizing radiation-induced DNA damage, nanoparticle-based radioconjugates for cancer therapy, and cellular responses to nanomaterials. 🌐🔬 Currently, she holds full professorships at both the Institute of Nuclear Chemistry and Technology in Warsaw and Jan Kochanowski University in Kielce, where she leads the Cytogenetics and Genotoxicology Laboratories. 💡📘 Her collaborative work spans across institutions in Germany, Finland, Belgium, and the USA. She is a respected academic leader, actively participating in global expert committees including WHO-IARC and the European Radiation Research Council. 🌍📚 With 85 peer-reviewed papers, 3797 citations, and an h-index of 30, Prof. Lankoff exemplifies excellence in research and education, making her an ideal candidate for the Best Researcher Award. 🏆🔝

Publication Profile

Orcid

Education 

Prof. Anna Lankoff began her academic journey with an MSc in Biology (1986–1991) from Jan Kochanowski University, Kielce, Poland. 🎓🔬 She earned her PhD in Toxicology in 1999 from Maria Sklodowska-Curie University in Lublin, Poland. 💊📘 Her research prowess led her to complete a prestigious postdoctoral fellowship in 2003 at Wright State University in Dayton, Ohio, USA, in the Department of Biological Sciences. 🌍🧬 In 2007, she achieved her DSc (habilitation) in Biological Sciences from the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences. 🧫📖 By 2014, she was awarded the title of Full Professor in Biological Sciences, marking a significant milestone in her academic career. 🌟 Her extensive academic preparation laid the foundation for a prolific scientific and educational path in radiobiology, cytogenetics, and nanotoxicology. 🧠💼

Experience 

Prof. Lankoff has an extensive academic and research career. Since 2014, she has been a Full Professor at both the Institute of Nuclear Chemistry and Technology, Warsaw, and Jan Kochanowski University, Kielce. 🧪🇵🇱 She leads laboratories in cytogenetics and genotoxicology. From 2009–2014, she served as Associate Professor at these institutions, and previously, as a lecturer and assistant since 1991. 📘👩‍🏫 Her international experience includes research stints at University of Duisburg-Essen (Germany), Wright State University (USA), VITO (Belgium), and Åbo Akademi University (Finland). 🌐🔍 She has mentored numerous students and professionals in molecular biology, immunology, and nanotoxicology. Her professional journey reflects dedication to excellence in both teaching and cutting-edge scientific research. 💡🧬

Awards and Honors 

Prof. Anna Lankoff’s contributions have been recognized internationally. 🌟 She was a working group member for the WHO-IARC (2006) and an expert for the EU’s “Epigenetic effects” radiation protection group (2017). 🌍🔬 She represented Poland on the ISO Radiology Standards Committee (2010–2015) and serves on the Scientific Council of the Institute of Nuclear Chemistry and Technology and the Polish Society for Radiation Research. 🇵🇱📘 She is also a member of the European Radiation Research Council since 2022. 🧪💡 Her work has earned her recognition for developing standards in biological dosimetry and contributions to nanotoxicology and radiation biology. 📜🔝 With a prolific academic record of 85 JCR-listed publications and over 3,700 citations, she holds an h-index of 30. 📚 Her impactful global collaborations, editorial work, and advisory roles highlight her as a true leader in radiobiological research and innovation. 🧬🏆

Research Focus 

Prof. Lankoff’s research integrates nanotechnology, radiobiology, and molecular biology. 🧬 Her focus areas include the genotoxicity and cytotoxicity of nanomaterials, development of nanoparticle-based radioconjugates for targeted cancer diagnosis and therapy, and the mechanisms of DNA damage and repair induced by ionizing radiation. 💥🧪 She investigates cellular responses such as cell cycle arrest, apoptosis, and pyroptosis in reaction to nanomaterial exposure and radiation treatment. 🧫 Her recent work explores nanotheranostics, blackcurrant-derived antioxidants, and radiosensitization strategies using natural compounds. 🌿💉 She also delves into biodistribution, pharmacokinetics of engineered nanostructures, and radiobiological safety, bridging basic science with translational medicine. 🌐🧠 Prof. Lankoff’s innovative research contributes to the development of safer nanomaterials and more effective cancer therapies, reinforcing her status as a pioneering researcher in modern molecular and radiation biology. 🧪🔬📈

Publication Top Notes

  1. 📘 Advances in Nanotheranostic Systems for Concurrent Cancer Imaging and Therapy: An Overview of the Last 5 Years (2024)

  2. 🧪 Nanoparticle-Based Radioconjugates for Targeted Imaging and Therapy of Prostate Cancer (2023)

  3. ☢️ Hypothermia Modulates NBS1, γH2AX and 53BP1 Foci in U2OS Cells Post Gamma Radiation (2022)

  4. 🍇 Blackcurrant Pomace Protects Rats from Testicular Oxidative Stress from Biodiesel Exhaust (2022)

  5. 🔬 Surface Modification of Gold Nanoparticles Triggers Pyroptosis-Inducing Cytokine Release (2022)

  6. 💉 Targeted NaA Nanozeolites for Prostate Cancer Therapy: Toxicity and Pharmacokinetics (2021)

  7. 🧬 Cisplatin Lowers Radiotherapy-Induced Micronuclei in Lymphocytes of Gynaecological Cancer Patients (2021)

  8. 📈 Coralyne Radiosensitizes A549 Cells by CDKN1A Upregulation Affecting G2/M Cell Cycle Arrest (2021)